BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18756533)

  • 21. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
    Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
    Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
    Buckley SA; Mawad R; Gooley TA; Becker PS; Sandhu V; Hendrie P; Scott BL; Wood BL; Walter RB; Smith K; Dean C; Estey EH; Pagel JM
    Br J Haematol; 2015 Aug; 170(3):349-55. PubMed ID: 25854284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
    Knoebel RW; McQuary A; Becker P; Hendrie P; Petersdorf S; Appelbaum FR; Estey E
    Leuk Res; 2011 Sep; 35(9):e164-6. PubMed ID: 21684006
    [No Abstract]   [Full Text] [Related]  

  • 26. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
    Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
    Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
    Kaya AH; Tekgündüz E; Ilkkiliç K; Dal MS; Merdin A; Karakus A; Hacioglu SK; Bekdemir F; Çakar MK; Dogu MH; Ayyildiz MO; Korkmaz S; Altuntaş F;
    J Chemother; 2018 Feb; 30(1):44-48. PubMed ID: 29098953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
    Alvarado Y; Tsimberidou A; Kantarjian H; Cortes J; Garcia-Manero G; Faderl S; Thomas D; Estey E; Giles FJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):87-90. PubMed ID: 12497211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
    Takahashi K; Kantarjian H; Garcia-Manero G; Borthakur G; Kadia T; DiNardo C; Jabbour E; Pierce S; Estrov Z; Konopleva M; Andreeff M; Ravandi F; Cortes J
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):163-8.e1-2. PubMed ID: 26752456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
    Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
    Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias.
    Carella AM; Pungolino E; Piatti G; Gaozza E; Nati S; Spriano M; Giordano D; D'Amico T; Damasio E
    Eur J Haematol; 1989 Oct; 43(4):309-13. PubMed ID: 2583257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.
    Jacoby MA; Martin MG; Uy GL; Westervelt P; Dipersio JF; Cashen A; Stockerl-Goldstein K; Vij R; Luo J; Reineck T; Bernabe N; Abboud CN
    Am J Hematol; 2014 May; 89(5):487-92. PubMed ID: 24415560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clofarabine-based consolidation therapy in AML.
    Brower V
    Lancet Oncol; 2017 Apr; 18(4):e201. PubMed ID: 28262461
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
    Fozza C
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):237-45. PubMed ID: 25457773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
    Faderl S; Balakrishnan K; Thomas DA; Ravandi F; Borthakur G; Burger J; Ferrajoli A; Cortes J; O'Brien S; Kadia T; Feliu J; Plunkett W; Gandhi V; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):231-8. PubMed ID: 24440659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
    Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
    Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
    Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
    Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.